Literature DB >> 19589728

Inflammation and colorectal cancer.

Sarah Kraus1, Nadir Arber.   

Abstract

Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC). However, the underlying mechanisms are not entirely clear. A genetic basis for the increased risk of CRC in IBD patients is only a partial explanation. It is possible that high levels of inflammatory mediators that are produced in this setting may contribute to the development and progression of CRC. Growing evidence supports a role for various cytokines, released by epithelial and immune cells, in the pathogenesis of IBD-associated neoplasia. Two key genes in the inflammatory process, cyclooxygenase-2 (COX-2) and nuclear factor kappaB (NF-kappaB), provide a mechanistic link between inflammation and cancer while other factors such as, TNF-alpha and IL-6-induced signaling have been recently shown to promote tumor growth in experimental models of colitis-associated cancer. This article reviews the pathogenesis of IBD-related CRC and summarizes the molecular mechanisms underlying the development of intestinal neoplasia in the setting of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589728     DOI: 10.1016/j.coph.2009.06.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  113 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

Review 3.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

4.  Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.

Authors:  Hong Peng; Qiang Su; Zhong-Chao Lin; Xiu-Hua Zhu; Ming-Sha Peng; Zhen-Bing Lv
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

5.  Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells.

Authors:  Li Hou; Bo Xu; Wei Guo; Fu-Xiang Ran; Jing-Tao Liu; Xia Yuan; Hong-Zheng Fu; Jing-Rong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

6.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

7.  Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease.

Authors:  Dominick L Auci; Nejat K Egilmez; Gerald W Dryden
Journal:  J Gastroenterol Pancreatol Liver Disord       Date:  2018-05-28

8.  Environmental Enrichment Induces Pericyte and IgA-Dependent Wound Repair and Lifespan Extension in a Colon Tumor Model.

Authors:  Benjamin D Bice; Megan R Stephens; Stephanie J Georges; Ashlee R Venancio; Peter C Bermant; Annika V Warncke; Kajsa E Affolter; Julio R Hidalgo; Melinda L Angus-Hill
Journal:  Cell Rep       Date:  2017-04-25       Impact factor: 9.423

Review 9.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.

Authors:  Rosaria Cammarota; Valentina Bertolini; Giuseppina Pennesi; Eraldo O Bucci; Ornella Gottardi; Cecilia Garlanda; Luigi Laghi; Massimo C Barberis; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.